Regulatory T cells move in when gliomas say "I Do".
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23052252.
- Also identified by DOI 10.1158/1078-0432.CCR-12-2801 and PMC identifier 3662964.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Indoleamine 2,3-dioxygenase (IDO) is an enzyme with known immunosuppressive and tolerogenic effects in cancer. Mounting evidence has associated IDO expression with the induction of regulatory T cells (Treg) and malignant progression. IDO inhibition may therefore provide a promising therapeutic approach for glioblastoma, where the need for novel treatment is great.
Medical subject headings
- Brain Neoplasms
- Glioblastoma
- Indoleamine-Pyrrole 2,3,-Dioxygenase
- T-Lymphocytes, Regulatory